These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8203859)

  • 1. Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice.
    Agarwal A; Kandpal H; Gupta HP; Singh NB; Gupta CM
    Antimicrob Agents Chemother; 1994 Mar; 38(3):588-93. PubMed ID: 8203859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections.
    Gupta CM; Haq W
    Methods Enzymol; 2005; 391():291-304. PubMed ID: 15721387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis.
    Owais M; Ahmed I; Krishnakumar B; Jain RK; Bachhawat BK; Gupta CM
    FEBS Lett; 1993 Jul; 326(1-3):56-8. PubMed ID: 8325389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters.
    Agrawal AK; Agrawal A; Pal A; Guru PY; Gupta CM
    J Drug Target; 2002 Feb; 10(1):41-5. PubMed ID: 11996085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuftsin-bearing liposomes in treatment of macrophage-based infections.
    Agrawal AK; Gupta CM
    Adv Drug Deliv Rev; 2000 Mar; 41(2):135-46. PubMed ID: 10699310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the Treatment of Infectious Diseases and Tumors.
    Khan MA
    Curr Drug Targets; 2021; 22(7):770-778. PubMed ID: 33243117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice.
    Khan MA; Nasti TH; Owais M
    J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles.
    Guru PY; Agrawal AK; Singha UK; Singhal A; Gupta CM
    FEBS Lett; 1989 Mar; 245(1-2):204-8. PubMed ID: 2538359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes.
    Labana S; Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2002 Oct; 20(4):301-4. PubMed ID: 12385689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice.
    Khan MA; Khan A; Owais M
    FEMS Immunol Med Microbiol; 2006 Feb; 46(1):63-9. PubMed ID: 16420598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice.
    Deol P; Khuller GK; Joshi K
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1211-4. PubMed ID: 9174172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
    Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2004 Apr; 23(4):414-5. PubMed ID: 15081096
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety, efficacy and pharmacokinetics of tuftsin-loaded nystatin liposomes in murine model.
    Khan MA; Faisal SM; Mohammad O
    J Drug Target; 2006 May; 14(4):233-41. PubMed ID: 16777682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.
    Diacon AH; Patientia RF; Venter A; van Helden PD; Smith PJ; McIlleron H; Maritz JS; Donald PR
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2994-6. PubMed ID: 17517849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functionalized rifampicin-loaded nanostructured lipid carriers enhance macrophages uptake and antimycobacterial activity.
    Carneiro SP; Carvalho KV; de Oliveira Aguiar Soares RD; Carneiro CM; de Andrade MHG; Duarte RS; Dos Santos ODH
    Colloids Surf B Biointerfaces; 2019 Mar; 175():306-313. PubMed ID: 30553206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections.
    Vall-Spinosa A; Lester W; Moulding T; Davidson PT; McClatchy JK
    N Engl J Med; 1970 Sep; 283(12):616-21. PubMed ID: 4988918
    [No Abstract]   [Full Text] [Related]  

  • 19. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
    Vernon A; Burman W; Benator D; Khan A; Bozeman L
    Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of rifampicin and isoniazid entrapped in liposomes for the treatment of Murine tuberculosis.
    Orozco LC; Quintana FO; Beltrán RM; de Moreno I; Wasserman M; Rodriguez G
    Tubercle; 1986 Jun; 67(2):91-7. PubMed ID: 3775869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.